• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β-d-N-羟基胞苷,莫那比拉韦的一种代谢物,表现出抗狂犬病毒的体外抗病毒活性。

β-d-N-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.

机构信息

Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan; Division of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.

出版信息

Antiviral Res. 2024 Sep;229:105977. doi: 10.1016/j.antiviral.2024.105977. Epub 2024 Jul 31.

DOI:10.1016/j.antiviral.2024.105977
PMID:39089332
Abstract

Rabies is a fatal neurological disorder caused by rabies virus (RABV) infection. Approximately 60,000 patients die from rabies annually, and there are no effective treatments for this disease. Nucleoside analogs are employed as antiviral drugs based on their broad antiviral spectrum, and certain nucleoside analogs have been reported to exhibit anti-RABV activity. The nucleoside analog β-d-N-hydroxycytidine (NHC) has antiviral effects against a range of RNA viruses. Molnupiravir (MPV), a prodrug of NHC, is clinically used as an oral antiviral drug for coronavirus infections. Despite its broad-spectrum activity, the antiviral activity of NHC against RABV remains unclear. In this study, we reveal that NHC exhibits comparable in vitro anti-RABV activity as ribavirin and favipiravir (also known as T-705) with a 90% effective concentration of 6 μM in mouse neuroblastoma cells. NHC reduced viral loads in neuronal and nonneuronal cells in a dose-dependent manner. Both laboratory and field RABVs (fixed and street strains, respectively) were susceptible to NHC. However, no increase in survival or reduction in viral titers in the brain was observed in RABV-infected mice treated prophylactically with MPV. These findings highlight the potential and challenges of NHC in the treatment of RABV infection.

摘要

狂犬病是一种由狂犬病病毒(RABV)感染引起的致命神经疾病。每年约有 6 万名患者死于狂犬病,目前尚无有效的治疗方法。基于其广谱抗病毒特性,核苷类似物被用作抗病毒药物,并且已经有报道称某些核苷类似物具有抗 RABV 活性。核苷类似物β-d-N-羟基胞苷(NHC)对多种 RNA 病毒具有抗病毒作用。NHC 的前药莫那比拉韦(MPV)已在临床上用作冠状病毒感染的口服抗病毒药物。尽管具有广谱活性,但 NHC 对 RABV 的抗病毒活性仍不清楚。在这项研究中,我们揭示 NHC 在体外具有与利巴韦林和法匹拉韦(也称为 T-705)相当的抗 RABV 活性,在小鼠神经母细胞瘤细胞中的 90%有效浓度为 6 μM。NHC 以剂量依赖性方式降低神经元和非神经元细胞中的病毒载量。实验室和现场 RABV(分别为固定株和街毒株)均对 NHC 敏感。然而,在预防性用 MPV 治疗的 RABV 感染小鼠中,未观察到存活或大脑中病毒滴度的增加。这些发现突出了 NHC 在治疗 RABV 感染方面的潜力和挑战。

相似文献

1
β-d-N-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus.β-d-N-羟基胞苷,莫那比拉韦的一种代谢物,表现出抗狂犬病毒的体外抗病毒活性。
Antiviral Res. 2024 Sep;229:105977. doi: 10.1016/j.antiviral.2024.105977. Epub 2024 Jul 31.
2
Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.法匹拉韦(T-705)在狂犬病暴露后预防中的疗效。
J Infect Dis. 2016 Apr 15;213(8):1253-61. doi: 10.1093/infdis/jiv586. Epub 2015 Dec 9.
3
Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus.利巴韦林相关化合物对狂犬病病毒具有体外抑制作用。
Antiviral Res. 2018 Jun;154:1-9. doi: 10.1016/j.antiviral.2018.03.011. Epub 2018 Mar 28.
4
Reevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis.利用体内成像分析重新评估法匹拉韦抗狂犬病毒的疗效。
Antiviral Res. 2019 Dec;172:104641. doi: 10.1016/j.antiviral.2019.104641. Epub 2019 Oct 28.
5
β-d--Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.β-d--羟基胞苷是一种有效的抗甲病毒化合物,可在病毒基因组中诱导高水平的突变。
J Virol. 2018 Jan 17;92(3). doi: 10.1128/JVI.01965-17. Print 2018 Feb 1.
6
Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.评价 I 型干扰素和不同抗病毒化合物对狂犬病病毒复制的体外抑制潜能。
Vaccine. 2019 Aug 2;37(33):4663-4672. doi: 10.1016/j.vaccine.2018.01.082. Epub 2018 Feb 17.
7
Small-Molecule Antiviral β-d--Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance.小分子抗病毒药物 β-d--羟基胞苷能抑制未经校正的冠状病毒,该病毒对耐药性有很高的遗传屏障。
J Virol. 2019 Nov 26;93(24). doi: 10.1128/JVI.01348-19. Print 2019 Dec 15.
8
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.莫努匹韦通过 RNA 模板促进 SARS-CoV-2 突变。
J Biol Chem. 2021 Jul;297(1):100770. doi: 10.1016/j.jbc.2021.100770. Epub 2021 May 11.
9
Re-evaluating the effect of Favipiravir treatment on rabies virus infection.重新评估法匹拉韦治疗狂犬病病毒感染的效果。
Vaccine. 2019 Aug 2;37(33):4686-4693. doi: 10.1016/j.vaccine.2017.10.109. Epub 2017 Nov 10.
10
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.Molnupiravir 和 Favipiravir 的联合治疗可增强 SARS-CoV-2 仓鼠感染模型中的抗病毒疗效。
EBioMedicine. 2021 Oct;72:103595. doi: 10.1016/j.ebiom.2021.103595. Epub 2021 Sep 24.